Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution

About this update from Kiniksa Pharmaceuticals International, Plc

[{"type":"text","content":"- Q3 2021 ARCALYST® (rilonacept) net revenue of $12.1 million -- ARCALYST prescribed by more than 200 physicians for recurrent pericarditis since approval -- Data from Phase 3 trial of mavrilimumab in COVID-19-related ARDS expected in Q1 2022 -- Data from Phase 2b trial of vixarelimab in prurigo nodularis expected in 2H 2022 -- Conference call and webcast scheduled for 8:30 am ET today - HAMILTON, Bermuda, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today reported third quarter 2021 financial results and recent portfolio execution. “We are delighted with the ARCALYST launch performance in recurrent pericarditis. The continued momentum underscores the dedication of our first-rate team as well as the unmet need for patients with this debilitating disease,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “In addition to our ongoing commercial efforts, we are executing on our clinical-stage pipeline. Mavrilimumab demonstrated potentially best-in-class mortality reduction in a Phase 2 study in non-mechanically ventilated patients with COVID-19-related ARDS, and Phase 3 data are on track for the first quarter of 2022. We are also conducting a dose-ranging Phase 2b study of vixarelimab in prurigo nodularis with data expected in the second half of 2022. Furthermore, we expect to initiate a Phase 2 proof-of-concept trial of KPL-404 in rheumatoid arthritis by the end of 2021.” Portfolio Execution ARCALYST (IL-1α and IL-1β cytokine trap) ARCALYST net revenue for the third quarter of 2021 was $12.1 million.More than 200 physicians have prescribed ARCALYST for recurrent pericarditis since approval.More than 90% of completed patient enrollment cases for recurrent pericarditis were approved for coverage.Kiniksa has achieved broad access for its recurrent pericarditis target population in the United States, with greater than 190 million lives receiving favorable coverage.Two thirds of ARCALYST prescriptions for recurrent pericarditis have been written for 12 months of therapy.Recent data from the ongoing Phase 3 clinical trial of ARCALYST in recurrent pericarditis (RHAPSODY) showed median duration of continuous ARCALYST therapy at the 1-year anniver...

More updates from Kiniksa Pharmaceuticals International, Plc